US FDA Lab Testing Policy Change
FDA has stopped accepting Indian lab results for medical device approvals, forcing Poly Medicure to retest all products in US labs. This has reversed prior work and created 6-9 month delays in the approval pipeline.
POLYMED / Q2-FY26 / risks
Keep the risk register visible.
Poly Medicure · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
European Competition and Inventory Realignment
Chinese competitors increased dumping in Europe due to US tariff diversion; combined with Panama Canal normalization reducing transit times from 2 months to 1 month, customer inventory destocking accelerated unexpectedly.
Renal Segment Guidance Reduction
Full-year renal guidance lowered from ₹220-250 crore to ₹200 crore due to GST-related inventory realignment in Q2. Management expects recovery from Q3 onward but did not quantify impact.
US Tariff Untenability
Analyst questioned whether 50% tariff on Indian medical devices is sustainable. Management acknowledged India is 'out of flavor' for US companies who are shifting to Vietnam, Thailand, Malaysia, Indonesia.